Royalty Pharma plc (RPRX) reports Q3 results; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mail
Get Alerts RPRX Hot Sheet
Join SI Premium – FREE
Royalty Pharma plc (NASDAQ: RPRX) reported Q3 resutls. Revenue for the quarter came in at $573 million versus the consensus estimate of $584.92 million.
GUIDANCE:
Adjusted Cash Receipts expected to be $2,750 to $2,800 million, which includes $458m from the acceleration of payments related to Pfizer’s acquisition of Biohaven.
For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana soars, Alignment Healthcare sinks on Medicare rating changes
- PepsiCo (PEP) Tops Q3 EPS by 4c, cuts EPS forecast
- Penguin Solutions (PENG) Tops Q4 EPS by 23c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
